A -- RECEPTOR PROFILING AND COMPOUND LIBRARY SCREENING

This is a SOURCES SOUGHT NOTICE to determine the availability of small businesses (e.g., 8(a), veteran-owned small businesses, services-disabled veteran owned small businesses, HUB Zone small businesses, small disadvantaged businesses, and women-owned small businesses) having capability to perform receptor profiling and compound library screening. ***SUMMARY OF OBJECTIVES: One of the primary objectives of the NIDA's Division of Pharmacotherapies and Medical Consequences of Drug Abuse is to develop medications for the treatment of drug abuse and its consequences. When a compound appears to be a possible therapeutic candidate, there is a need for more extensive receptor profiling to insure that biological activity is specific to the systems of interest. Extensive profiling lessens the possibility of unexpected side effects in biological systems not specifically studied in the initial screens. This contract will provide a mechanism to profile selected compounds at a wide variety of receptor targets, ion channels and enzyme sites to assess the potential for side effects. The contract allows screening of a large number of substances from pharmaceutical or chemical compound libraries at selected receptors to discover novel compounds with specified biological activity. ***THE CONTRACTOR should be able to perform the following assays as a core battery, but also have the capacity to perform or develop other assays as needed by NIDA: NEUROTRANSMITTER related: Adenosine, non-selective; Adrenergic, alpha-1, non-selective;Adrenergic, alpha-2, non-selective; Adrenergic, beta-1;Cannabinoid, CB1; Cannabinoid, CB2;Dopamine, D4.2; GABA-A, agonist site; GABA-A, BDZ, alpha-1 site; GABA-B; Glutamate, AMPA site; Glutamate, Kainate site; Glutamate, NMDA agonist site; Glutamate, mGluR1 (metabotropic); Glutamate, mGluR5 (metabotropic); Glutamate, NMDA, Glycine (strychnine-insensitive site) (ionotropic); Glutamate, NMDA, PCP Site; Glycine, strychnine-sensitive; Histamine, H1; Histamine, H2; Histamine, H3; Muscarinic, M1; Muscarinic, M2;Muscarinic, non-selective, central; Muscarinic, non-selective, peripheral; Nicotinic, Muscle (a-BnTx sensitive); Nicotinic, Neuronal (a-BnTx insensitive); Opioid, non-selective; **STEROIDS: Glucocorticoid; Testosterone; **ION CHANNELS: Calcium Channel, Type L (Benzothiazepine site); Calcium Channel, Type L (Dihydropyridine site); Calcium Channel, Type N; Potassium Channel, ATP-sensitive; Potassium Channel, Ca2+, Act. VI; Sodium, Site 2; **SECOND MESSENGERS: Nitric Oxide, NOS Neuronal binding); **PROSTAGLANDINS: Leukotriene, LTB4 (BLT1); Leukotriene, TD4 (CysLT1); Thromboxane A2; **GROWTH FACTORS/HORMONES: Corticotropin releasing factor, non-selective; Oxytocin; Platelet Activating Factor (PAF); Thyrotropin releasing hormone (TRH); **BRAIN/GUT PEPTIDES: Angiotensin II AT1; Angiotensin II AT2; Bradykinin, BK2; Cholecystokinin, CCK1 (CCKA); Cholecystokinin, CCK2 (CCKB); Endothelin, ET-A; Endothelin, ET-B; Galanin, non-selective; Neurokinin, NK1; Neurokinin, NK2 (NKA); Neurokinin, NK3 (NKB); Vasoactive intestinal peptide, non-selective; Vasopressin 1; **ENZYMES: Decarboxylase, Glutamic acid; Esterase, Acetylcholine; Oxidase, MAO-A, peripheral; Oxidase, MAO-B, peripheral; Transferase, Choline Acetyl; **CYTOCHROME P450: CYP1A2; CYP2A6; CYP2C19; CYP2C9*1; CYP2D6; CYP3A4;***THIS IS NOT A REQUEST FOR PROPOSALS: This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. The Government does not intend to award a contract based on responses under this announcement nor otherwise pay for preparing any information sent for the Government's use. Any proprietary information should be so marked. Interested organizations must be able to demonstrate,1) in a brief narrative response, extensive experience in the following areas: a) performing receptor, functional, and enzyme assays (see list) using state-of-the-art assay methodologies; b) performing high throughput screening of a large number of compounds at a single receptor or transporter target, with appropriate follow up assays; c) personnel with the knowledge of, expertise in evaluation, and experience, along with equipment, instrumentation, and facility to perform Items 1 and 2, and; d) DEA Research Registration for Schedules II to V. In addition, interested organizations are required to identify your type of business or organization, its size (number of employees and gross annual revenue), your eligibility under 8(a) or other set-aside programs, as applicable (Note: The applicable NAICS code for this requirement is 541711, 500 employees); and 3) other resources available (e.g. scientific equipment, laboratory facilities, etc.). Written capability statements must be SUBMITTED NO LATER THAN NOVEMBER 14, 2007 to NIDA, 6101 Executive Boulevard, Room 260, MSC 8402, Bethesda, MD 20892-8402, Attn: Diane Loeb.